News | July 31, 2007

New Technology May Lead to Earlier Cancer Detection

August 1, 2007 - The results of a pilot study on a new optical technology, coupled with routine endoscopy, presented in the Aug. 1 issue of Clinical Cancer Research, could represent a new approach to detecting pancreatic cancer at a very early stage.

Developed by Northwestern University biomedical engineers, the new optical technology, with routine endoscopy, exposes cellular changes indicative of cancer in tissue near the pancreas that had previously been detectable only through intensive radiologic scanning or invasive surgery.

“Pancreatic cancer is not often detected early because it is a rather inaccessible organ, so this technique holds the potential to be the first reliable, routine screening tool for pancreatic cancer,” said co-author author Randall Brand, M.D., an associate professor of medicine at Northwestern University and clinician at Evanston Northwestern Healthcare. “If we could apply this to those at high risk – such as people with chronic pancreatitis or who have a family history of pancreatic cancer– we might see a drastic improvement in pancreatic cancer survival.”

The optical technology used to detect the field effect of pancreatic cancer was developed by the senior author of the study Vadim Backman, Ph.D., a professor of biomedical engineering at Northwestern along with his graduate student, Yang Liu, Ph.D, the first author on the report. With a single instrument, Backman can use two different means of detecting the optical properties of a tissue sample, both of which were developed in his laboratory: four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS).

“We are able to use the optical properties of a cell’s structure to serve as a marker for disease,” said Backman. “These are changes within the tissue that cannot be detected through any other means. Neither antibodies nor diagnostic assays can detect them.”

According to Backman, optical markers are independent of other factors within the tissue microenvironment. “The markers do not change if the patient is a smoker. And the markers do not change with the location, stage or size of the tumor in the pancreas,” he said.

Researchers are currently involved in a larger study of the technique and its refinement. They estimate that the technology may be put into practice within three years.

The study was supported by funding from the National Science Foundation and the National Institutes of Health.

For more information: www.aacr.org

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
Eight Proton Therapy Centers Worldwide Adopt RayStation for Treatment Planning
News | Treatment Planning | July 21, 2017
RaySearch Laboratories reported that eight additional proton therapy centers worldwide have recently chosen RayStation...
Catharina Hospital

Catharina Hospital

Sponsored Content | Case Study | Treatment Planning | July 05, 2017
Recently, the oncology department needed to update its radiation therapy treatment planning system. The department...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
IBA and Philips Step Up Commercial Collaboration in Brazilian Proton Therapy Market
News | Radiation Therapy | July 03, 2017
IBA and Philips announced in mid-June they are stepping up their combined effort for proton therapy in Brazil.
Proton Monte Carlo Dose Calculation Now Part of RayStation Treatment Planning
News | Treatment Planning | May 15, 2017
RaySearch demonstrated a new Monte Carlo dose planning feature for proton therapy on its RayStation system at the 2017...
Nottingham City Hospital Selects RayStation for Radiotherapy Treatment Planning
News | Treatment Planning | April 28, 2017
Nottingham City Hospital in the United Kingdom has chosen RayStation as the new treatment planning system for its...
RayStation 6, new release, RaySearch Laboratories, radiation therapy, treatment planning, TomoTherapy
Technology | Treatment Planning | February 01, 2017
RayStation 6, the latest release of RaySearch’s radiation therapy treatment planning system, adds significant new...
Overlay Init